Both Pfizer And GSK RSV Vaccines Set For Approval – But Could Next Readouts Give One The Edge?
Longer Term Data Ready Soon
Executive Summary
The two frontrunners look set to gain US FDA approval, but will need more robust long-term data to convince frontline physicians and payers of benefits to at-risk individuals.